July 1968

Experience with Arteriovenous Shunts in Leukemic Patients

Author Affiliations

Upton, NY
From the Medical Research Center, Brookhaven National Laboratory, Upton, NY. Dr. Stryckmans is presently with the Institut Jules Bordet, Brussels; and Dr. Greenberg is with the Mount Sinai School of Medicine, New York.

Arch Surg. 1968;97(1):154-160. doi:10.1001/archsurg.1968.01340010184026

THE TEFLON arteriovenous shunt (AV shunt), originally developed by Quinton et al1 for use with the artificial kidney, has generally been adopted for extracorporeal irradiation of the circulating blood (ECIB) in the experimental therapy of human leukemia by us2-4 and others.5,6 The problems associated with the long-term management of these shunts in patients with chronic renal insufficiency have been discussed by other workers.7-9 Our experience has differed from that reported in patients with chronic renal failure and we, therefore, considered it pertinent to publish our findings in the hope that these might prove to be of some use to investigators employing ECIB in leukemic patients.

Materials and Methods  Thirty-three patients with leukemia, admitted to the hospital of the Medical Research Center, Brookhaven National Laboratory, from November 1964 to March 1967 have been treated by ECIB. Sixteen of these patients had acute myelocytic leukemia (AML), 11 patients

First Page Preview View Large
First page PDF preview
First page PDF preview